Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514300 | 0.93 | HSD11B1 (0.52) | HSD11B1EPHX2MAPK8P2RX7ALDH1A1 | |
| SCHEMBL4501264 | 0.93 | HSD11B1 (0.50) | HSD11B1ALDH1A1GAA | |
| SCHEMBL4515610 | 0.91 | HSD11B1 (0.52) | HSD11B1ALDH1A1GAA | |
| SCHEMBL4515193 | 0.91 | HSD11B1 (0.51) | HSD11B1MAPK8P2RX7ALDH1A1GAA | |
| SCHEMBL4505990 | 0.91 | HSD11B1 (0.47) | HSD11B1EPHX2CYP2C19P2RX7ALDH1A1 | |
| SCHEMBL4502708 | 0.90 | HSD11B1 (0.59) | HSD11B1MAPK8ALDH1A1GAA | |
| SCHEMBL4518942 | 0.89 | HSD11B1 (0.50) | HSD11B1ALDH1A1GAA | |
| SCHEMBL4505009 | 0.89 | HSD11B1 (0.49) | HSD11B1ALDH1A1GAA | |
| SCHEMBL4513448 | 0.88 | HSD11B1 (0.49) | HSD11B1EPHX2P2RX7ALDH1A1GAA | |
| SCHEMBL4516875 | 0.88 | HSD11B1 (0.47) | HSD11B1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885EPHX2 670/4885CYP2C9 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.